PPT-Pharmacotherapy Considerations in Sepsis and COVID-19
Author : RainbowGlow | Published Date : 2022-08-01
Eli Opacich PharmD BCPS BCCCP December 2 nd 2020 Financial Disclosures None Learning Objectives Assess pharmacotherapy updates in sepsis and septic shock Employ
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Pharmacotherapy Considerations in Sepsis..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Pharmacotherapy Considerations in Sepsis and COVID-19: Transcript
Eli Opacich PharmD BCPS BCCCP December 2 nd 2020 Financial Disclosures None Learning Objectives Assess pharmacotherapy updates in sepsis and septic shock Employ antimicrobial stewardship practices related . Laura Evans, MD MSc. Medical Director of Critical Care. Bellevue Hospital. NYU School of Medicine. Disclosures. No conflicts of interest to disclose. Outline. Burden of sepsis. Surviving Sepsis Campaign. program . (general overview). add . LHD and/or hospital name. Aims. Provide an overview of the SEPSIS KILLS program . and its impact in this LHD/facility. Outline the elements of the inpatient SEPSIS KILLS program. Wade Woelfle, MD, FAAEM. UW ECC 2016. June 21,2016. Sepsis Objectives. Definition. Why and how it happens. Identification. Similar problems. Monitoring. Treatments. New and revisited developments. Sepsis. Dr. Vida Hamilton. National Clinical Lead Sepsis. www.hse.ie/sepsis. Sepsis - 2. A dysregulated immune response to infection. Regulated. Innate & Adaptive. Cellular: Dendritic cells, T-cells, B-cells. Stage 1. Source: world-sepsis-day.org . What is Sepsis?. Source: world-sepsis-day.org . Sepsis at a Glance. Sepsis is a . medical emergency . . . . . Source: . Advisory Board Company: “Why sepsis screening isn't one-size-fits-all” . Early Goal Directed Therapy. and Beyond. Anthony J. Hericks, D.O.. South Dakota. ACP. Scientific Meeting. September 13. th. , . 2013. A clinician, armed with the sepsis bundles, attacks the three heads of severe sepsis: hypotension, hypoperfusion and organ dysfunction. . COI Disclosures. Evans – Nothing to disclose. Thank You. Guidelines panelists. Group Heads. Methodologists. SCCM and ESICM . Participating societies. Reviewers. Dr. Phil Dellinger. Ms. Deb . Mcbride. Objectives. “Sepsis is caused when the body’s . immune system becomes overactive in response to an infection. , causing inflammation which can affect how well other tissues and organs work.”. –National Institute for Health and Care Excellence Guidelines. MLP EM Education Curriculum. Dave Markel. September 15, 2015. What will be covered. Basic concepts and definitions. Initial management. Septic shock. Pearls and pitfalls. What will . not. be covered. Maureen Campion, PharmD. Clinical Pharmacy Specialist- Infectious Disease. UMass Memorial Medical Center . Disclosure statement. I have no actual or potential conflict of interest . in relation to this program/presentation.. Source and Credits. This presentation is based on the October 2018. AHRQ . WebM&M. Spotlight Case. See the full article at https://psnet.ahrq.gov/webmm. CME credit is available. Commentary by: . Paula McDonagh . Lead Nurse-Sepsis. CHFT . What is sepsis.. Sepsis is when your body flights too hard against an infection.. Sometimes important body parts are damaged such as the kidneys, liver . and circulation. Sepsis Redefinition (Sepsis-3). February 23, 2016. Announced at the SCCM meeting in Orlando on February 22, 2016. Published in JAMA on February 23, 2016. http://www.tinyurl.com/2016sepsis. . The SIRS Criteria is valid to the extent that a systemic inflammatory response can be triggered by a variety of infectious and non-infectious conditions.. Sepsis,. . TNF-α. . Association. . with. . Mortality. . but. . not. . Sepsis. . Severity. . or. . Infection. . Source:. . a. . Systematic. . Review. and. . Meta-analysis. Amal. . A..
Download Document
Here is the link to download the presentation.
"Pharmacotherapy Considerations in Sepsis and COVID-19"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents